Dong Zhou1, Jinbin Xu2, Cedric Mpoy3, Wenhua Chu2, Sung Hoon Kim4, Huifangjie Li2, Buck E Rogers3, John A Katzenellenbogen4. 1. Department of Radiology, School of Medicine, Washington University in Saint Louis, Saint Louis, MO 63110, United States of America. Electronic address: zhoud@wustl.edu. 2. Department of Radiology, School of Medicine, Washington University in Saint Louis, Saint Louis, MO 63110, United States of America. 3. Radiation Oncology, School of Medicine, Washington University in Saint Louis, Saint Louis, MO 63110, United States of America. 4. Department of Chemistry, University of Illinois at Urbana-Champaign, IL 61801, United States of America.
Abstract
INTRODUCTION: Poly (ADP-ribose) polymerase-1 (PARP-1) plays many roles in prostate cancer (PC), such as mediating DNA damage repair, transcriptional regulation and nuclear hormone receptor signaling. Because of this, PARP-1 has been targeted for therapy in PC, and non-invasive imaging of PARP-1 could help predict which patients are likely to respond to such therapy. Several PARP-1 positron emission tomography (PET) imaging agents have been developed and show promise for imaging PARP-1 expression in breast, brain, and lung cancer in small animals, but not as yet in prostate cancer. [18F]WC-DZ-F is an analogue of [18F]FluorThanatrace (FTT) and [125I]KX1, which are well-established PARP-1 ligands for measuring PARP-1 expression. Herein, we evaluated the potential of [18F]WC-DZ-F for the imaging PARP-1 expression in PC. METHODS: [18F]WC-DZ-F was synthesized by a two-step sequence. [18F]WC-DZ-F was evaluated by in vitro uptake studies in PC-3 cells and by in vivo biodistribution and microPET imaging using PC-3 tumor xenografts. Ex vivo autoradiography of PC-3 tumors after microPET imaging was also performed. RESULTS: [18F]WC-DZ-F has high, PARP-1-specific uptake in PC-3 cells. In the microPET imaging study, [18F]WC-DZ-F accumulated in PC-3 xenograft tumors over 2 h, and the uptake was significantly reduced by blocking with olaparib. PC-3 tumors were clearly visualized in microPET images, and the imaging results were further confirmed by autoradiography of PC-3 tumors ex vivo. In the biodistribution study [18F]WC-DZ-F washed out quickly from most tissues within 2 h, except for the liver in which the uptake was not blockable by olaparib. CONCLUSIONS: We synthesized a novel PARP-1 radioligand, [18F]WC-DZ-F. The preliminary evaluation of [18F]WC-DZ-F indicates that it is a suitable PET imaging agent for measuring PARP-1 expression in prostate cancer and should be applicable to other types of cancers.
INTRODUCTION:Poly (ADP-ribose) polymerase-1 (PARP-1) plays many roles in prostate cancer (PC), such as mediating DNA damage repair, transcriptional regulation and nuclear hormone receptor signaling. Because of this, PARP-1 has been targeted for therapy in PC, and non-invasive imaging of PARP-1 could help predict which patients are likely to respond to such therapy. Several PARP-1 positron emission tomography (PET) imaging agents have been developed and show promise for imaging PARP-1 expression in breast, brain, and lung cancer in small animals, but not as yet in prostate cancer. [18F]WC-DZ-F is an analogue of [18F]FluorThanatrace (FTT) and [125I]KX1, which are well-established PARP-1 ligands for measuring PARP-1 expression. Herein, we evaluated the potential of [18F]WC-DZ-F for the imaging PARP-1 expression in PC. METHODS:[18F]WC-DZ-F was synthesized by a two-step sequence. [18F]WC-DZ-F was evaluated by in vitro uptake studies in PC-3 cells and by in vivo biodistribution and microPET imaging using PC-3tumor xenografts. Ex vivo autoradiography of PC-3tumors after microPET imaging was also performed. RESULTS:[18F]WC-DZ-F has high, PARP-1-specific uptake in PC-3 cells. In the microPET imaging study, [18F]WC-DZ-F accumulated in PC-3 xenograft tumors over 2 h, and the uptake was significantly reduced by blocking with olaparib. PC-3tumors were clearly visualized in microPET images, and the imaging results were further confirmed by autoradiography of PC-3tumors ex vivo. In the biodistribution study [18F]WC-DZ-F washed out quickly from most tissues within 2 h, except for the liver in which the uptake was not blockable by olaparib. CONCLUSIONS: We synthesized a novel PARP-1 radioligand, [18F]WC-DZ-F. The preliminary evaluation of [18F]WC-DZ-F indicates that it is a suitable PET imaging agent for measuring PARP-1 expression in prostate cancer and should be applicable to other types of cancers.
Authors: Loren S Michel; Samantha Dyroff; Frank J Brooks; Katherine J Spayd; Sora Lim; Jacquelyn T Engle; Sharon Phillips; Benjamin Tan; Andrea Wang-Gillam; Christopher Bognar; Wenhua Chu; Dong Zhou; Robert H Mach; Richard Laforest; Delphine L Chen Journal: Radiology Date: 2016-11-14 Impact factor: 11.105
Authors: Christine E Edmonds; Mehran Makvandi; Brian P Lieberman; Kuiying Xu; Chenbo Zeng; Shihong Li; Catherine Hou; Hsiaoju Lee; Roger A Greenberg; David A Mankoff; Robert H Mach Journal: Am J Nucl Med Mol Imaging Date: 2016-01-28
Authors: Filip Zmuda; Gaurav Malviya; Adele Blair; Marie Boyd; Anthony J Chalmers; Andrew Sutherland; Sally L Pimlott Journal: J Med Chem Date: 2015-10-27 Impact factor: 7.446
Authors: M Salemi; A Galia; F Fraggetta; C La Corte; P Pepe; S La Vignera; G Improta; P Bosco; A E Calogero Journal: Eur J Histochem Date: 2013-04-15 Impact factor: 3.188
Authors: Ruud van der Noll; Serena Marchetti; Neeltje Steeghs; Jos H Beijnen; Marja W J Mergui-Roelvink; Emmy Harms; Harriet Rehorst; Gabe S Sonke; Jan H M Schellens Journal: Br J Cancer Date: 2015-07-16 Impact factor: 7.640
Authors: Mehran Makvandi; Kuiying Xu; Brian P Lieberman; Redmond-Craig Anderson; Samuel Sander Effron; Harrison D Winters; Chenbo Zeng; Elizabeth S McDonald; Daniel A Pryma; Roger A Greenberg; Robert H Mach Journal: Cancer Res Date: 2016-06-03 Impact factor: 13.312
Authors: Paula Demétrio de Souza França; Navjot Guru; Abigail R Kostolansky; Audrey Mauguen; Giacomo Pirovano; Susanne Kossatz; Sheryl Roberts; Marcio Abrahão; Snehal G Patel; Kay J Park; Thomas Reiner; Elizabeth Jewell Journal: J Nucl Med Date: 2020-11-13 Impact factor: 10.057
Authors: Sophie Stotz; Johannes Kinzler; Anne T Nies; Matthias Schwab; Andreas Maurer Journal: Eur J Nucl Med Mol Imaging Date: 2021-09-06 Impact factor: 9.236
Authors: Dong Zhou; Huaping Chen; Cedric Mpoy; Sadia Afrin; Buck E Rogers; Joel R Garbow; John A Katzenellenbogen; Jinbin Xu Journal: Biomedicines Date: 2021-05-18